TAIHUSNOW CO.,LTD.
838262
Guangdong Brandmax Marketing
300805
Guangdong Transtek Medical Electronics
300562
Suzhou Kingswood Education Technology
300192
Broadex Technologies
300548
CN Stock MarketDetailed Quotes
000739 Apeloa Pharmaceutical
- 16.11
- -0.16-0.98%
Trading Dec 16 10:09 CST
18.84BMarket Cap17.55P/E (TTM)
16.40High16.08Low15.72KlotVolume16.38Open16.27Pre Close25.47MTurnover0.13%Turnover Ratio17.84P/E (Static)1.17BShares18.9652wk High2.86P/B18.83BFloat Cap10.3552wk Low17.90Limit Up1.17BShs Float40.98Historical High14.64Limit Down1.97%Amplitude-1.06Historical Low0.32Dividend TTM16.21Avg Price11.38KlotAsk1.97%Div YieldTTM100Lot Size3.90KlotBid
Apeloa Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | 24.80%7.47B | 32.88%5.19B | 15.09%2.3B | 21.73%8.86B | 9.75%5.99B | 10.91%3.91B | 45.78%2B | 14.62%7.28B | 17.50%5.45B | 16.40%3.52B |
| Refunds of taxes and levies | 2.88%377.27M | -8.24%247.59M | -9.57%119.07M | 6.15%484.13M | 11.09%366.71M | 31.42%269.83M | 34.79%131.67M | 47.86%456.08M | 46.77%330.1M | 26.80%205.31M |
| Cash received relating to other operating activities | -9.01%235.14M | -18.75%134.82M | -14.92%45.15M | 37.44%328.21M | 15.29%258.41M | 9.80%165.93M | 17.07%53.06M | 18.74%238.8M | 38.26%224.15M | 96.93%151.11M |
| Cash inflows from operating activities | 22.26%8.08B | 28.36%5.57B | 12.87%2.46B | 21.31%9.68B | 10.03%6.61B | 11.95%4.34B | 44.21%2.18B | 16.24%7.98B | 19.48%6.01B | 18.81%3.88B |
| Goods services cash paid | 24.85%5.24B | 34.57%3.4B | 9.60%1.48B | 36.12%6.46B | 12.02%4.2B | -1.18%2.53B | 85.80%1.35B | 6.82%4.74B | 22.61%3.75B | 32.62%2.56B |
| Staff behalf paid | 7.80%668.3M | 8.83%487.67M | 5.76%310.07M | 14.28%941.81M | 17.85%619.94M | 17.81%448.1M | 18.07%293.18M | 15.45%824.14M | 18.16%526.06M | 18.21%380.36M |
| All taxes paid | 3.81%408.64M | 10.85%326.14M | 55.85%191.19M | 16.21%481.25M | 5.08%393.64M | 2.00%294.21M | -29.49%122.67M | -9.66%414.11M | -12.63%374.62M | -25.86%288.45M |
| Cash paid relating to other operating activities | 8.74%599.55M | 14.31%375.91M | 4.38%196.65M | 14.33%762.06M | 12.59%551.38M | 1.97%328.85M | -0.77%188.4M | 4.88%666.53M | 11.89%489.72M | 7.07%322.51M |
| Cash outflows from operating activities | 20.03%6.92B | 27.58%4.59B | 11.42%2.18B | 29.99%8.64B | 12.16%5.76B | 1.40%3.6B | 46.05%1.96B | 6.40%6.65B | 17.62%5.14B | 20.70%3.55B |
| Net cash flows from operating activities | 37.38%1.17B | 32.11%980.78M | 25.65%280.13M | -22.23%1.03B | -2.55%848.54M | 126.07%742.37M | 29.85%222.94M | 116.77%1.33B | 31.74%870.77M | 1.61%328.38M |
| Investing cash flow | ||||||||||
| Cash received from disposal of investments | 363.44%209.82M | ---- | ---- | -86.41%52.1M | --45.27M | --8.01M | ---- | -28.96%383.25M | ---- | ---- |
| Cash received from returns on investments | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -99.69%222.13K | -99.55%164.57K |
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | 1,790.28%2.14M | 25,614.23%1.31M | ---- | 84.03%8.96M | -53.14%113.26K | -96.37%5.1K | ---- | 25.66%4.87M | -86.04%241.67K | --140.32K |
| Net cash received from disposal of subsidiaries and other business units | -75.00%7.6M | -75.00%7.6M | --7.6M | --30.4M | --30.4M | --30.4M | ---- | ---- | ---- | ---- |
| Cash received relating to other investing activities | -7.53%23.89M | -4.77%23.82M | ---- | 10.62%35.15M | 6.67%25.84M | 99.94%25.01M | -39.72%4.9M | -59.23%31.78M | 220.71%24.22M | 65.64%12.51M |
| Cash inflows from investing activities | 139.56%243.45M | -48.40%32.73M | 55.18%7.6M | -69.85%126.62M | 311.68%101.62M | 394.99%63.43M | -41.49%4.9M | -34.49%419.89M | -85.41%24.68M | -90.38%12.81M |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | -11.08%370.82M | 1.51%225.47M | 2.13%195.49M | 23.84%630.47M | 2.67%417.05M | -40.58%222.12M | -13.67%191.42M | -27.47%509.11M | -33.74%406.22M | 17.34%373.81M |
| Cash paid to acquire investments | 66.83%205.53M | -88.00%6M | ---- | -66.58%130M | 1,953.33%123.2M | --50M | ---- | -12.95%389.03M | --6M | ---- |
| Cash paid relating to other investing activities | 42.62%31.63M | 9.21%22.53M | -96.86%251.43K | -62.01%42.95M | -65.26%22.18M | -46.23%20.63M | --8M | 1,415.67%113.06M | 679.22%63.84M | 368.23%38.36M |
| Cash outflows from investing activities | 8.10%607.99M | -13.24%254M | -1.84%195.74M | -20.55%803.41M | 18.14%562.42M | -28.97%292.74M | -10.07%199.42M | -12.55%1.01B | -23.37%476.06M | 26.14%412.17M |
| Net cash flows from investing activities | 20.89%-364.54M | 3.51%-221.27M | 3.28%-188.14M | -14.46%-676.8M | -2.09%-460.8M | 42.58%-229.31M | 8.83%-194.52M | -14.73%-591.3M | 0.14%-451.38M | -106.40%-399.35M |
| Financing cash flow | ||||||||||
| Cash received from capital contributions | 34.68%505.05K | --505.05K | ---- | -94.90%375K | -94.90%375K | ---- | ---- | --7.35M | --7.35M | ---- |
| -Including: Cash received from capital contributions by minority shareholders of subsidiaries | 34.68%505.05K | --505.05K | ---- | -94.90%375K | -94.90%375K | ---- | ---- | --7.35M | --7.35M | ---- |
| Cash from borrowing | -1.95%1.01B | -23.74%530M | -45.83%260M | -2.24%1.06B | 2.87%1.03B | 3.96%695M | -9.94%480M | 34.81%1.09B | 26.92%996.44M | -4.79%668.5M |
| Cash inflows from financing activities | -1.94%1.01B | -23.67%530.51M | -45.83%260M | -2.86%1.06B | 2.15%1.03B | 3.96%695M | -9.94%480M | 35.72%1.09B | 27.86%1B | -4.79%668.5M |
| Borrowing repayment | 2.59%974.84M | -18.20%463.94M | -42.90%210M | 35.35%964.67M | 70.50%950.2M | 107.61%567.2M | 122.91%367.8M | 2.08%712.71M | -11.13%557.3M | -45.37%273.2M |
| Dividend interest payment | 6.59%400.95M | 7.59%392.17M | 37.04%11.72M | 5.57%383.02M | 5.42%376.17M | 4.37%364.5M | 72.27%8.55M | 20.17%362.8M | 14.70%356.84M | 19.50%349.24M |
| Cash payments relating to other financing activities | 1,843.67%162.24M | 8,682.96%152.68M | -1.89%761.42K | -92.80%15.35M | -95.97%8.35M | -99.00%1.74M | --776.08K | 2,178.24%213.37M | --207.14M | --173.86M |
| Cash outflows from financing activities | 15.23%1.54B | 8.07%1.01B | -41.01%222.48M | 5.75%1.36B | 19.03%1.33B | 17.22%933.44M | 121.89%377.13M | 27.68%1.29B | 19.52%1.12B | 0.50%796.3M |
| Net cash flows from financing activities | -72.15%-532.53M | -100.60%-478.3M | -63.53%37.52M | -53.75%-301.48M | -163.29%-309.34M | -86.58%-238.44M | -71.66%102.87M | 4.03%-196.09M | 23.26%-117.49M | -41.60%-127.8M |
| Net cash flow | ||||||||||
| Exchange rate change effecting cash and cash equivalents | -87.39%4.43M | -17.12%31.18M | 238.23%7.08M | -37.57%27.49M | -36.74%35.15M | 81.13%37.62M | -55.54%-5.12M | 354.29%44.04M | 983.54%55.57M | 409.69%20.77M |
| Net increase in cash and cash equivalents | 140.48%273.07M | 0.05%312.4M | 8.26%136.59M | -86.17%80.57M | -68.24%113.55M | 275.42%312.25M | -60.33%126.17M | 565.14%582.76M | 621.45%357.48M | -643.80%-178M |
| Add:Begin period cash and cash equivalents | 3.38%2.46B | 3.38%2.46B | 3.38%2.46B | 32.39%2.38B | 32.39%2.38B | 32.39%2.38B | 32.39%2.38B | -6.51%1.8B | -6.51%1.8B | -6.51%1.8B |
| End period cash equivalent | 9.62%2.74B | 3.00%2.77B | 3.63%2.6B | 3.38%2.46B | 15.71%2.5B | 66.19%2.69B | 18.46%2.51B | 32.39%2.38B | 9.25%2.16B | -17.17%1.62B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Hexin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Hexin Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
